Kitov Pharma is a clinical-stage company that advances first-in-class therapies to overcome tumor-immune evasion and drug resistance in order to create successful, long-lasting treatments for patients with hard-to-treat cancers.
Kitov’s oncology pipeline comprises two drugs. CM-24 is a monoclonal antibody blocking CEACAM1, a novel immune checkpoint that supports tumor-immune evasion and survival through multiple pathways. NT-219 is a potential first-in-class small molecule bi-specific inhibitor of two key cancer resistance pathways – STAT3 and IRS1/2.
Prior to focusing on oncology, Kitov developed Consensi™, a fixed-dose combination of celecoxib and amlodipine besylate for the simultaneous treatment of osteoarthritis pain and hypertension. The drug was approved by the US Food and Drug Administration (FDA) for marketing in the US in 2018. Consensi™ is expected to be launched in H1 2020 by Kitov’s partner Coeptis Pharmaceuticals. Kitov has also partnered to commercialize Consensi™ in China and South Korea.
CONTACT US https://kitovpharma.com/